Evidence base: Acromegaly

Find all the latest information about guidelines, online resources and key texts on the management of acromegaly

MRI scan showing acromegaly (Photograph: SPL)
MRI scan showing acromegaly (Photograph: SPL)

Clinical trials

This is a review of the largest studies of somatostatins, subcutaneous octreotide, octreotide long-acting formulation (LAR), and slow releasing (SR) lanreotide, which included biochemical end-point data for lanreotide autogel (ATG), and also studies that directly compared the efficacy of octreotide LAR and lanreotide SR.

It concluded that lanreotide ATG and octreotide LAR are equivalent in the control of symptoms.

  • Trainer PJ, Ezzat S, D'Souza GA. A randomised, controlled, multicenter trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol 2009; 71: 549-57.

The outcome of this study was that pegvisomant monotherapy and adjunctive therapy are viable options for the treatment of patients with acromegaly who are suboptimally controlled on long-acting octreotide.

Guidelines

Key Texts

  • Turner HE, Wass JAH. Oxford Handbook of Endocrinology and Diabetes. 2nd edition. Oxford, Oxford University Press, 2009.
  • Wass JAH. Acromegaly: A handbook of history, current therapy and future prospects. BioScientific, 2009.

Online resources

 

Contributed by Dr Raghava Reddy, consultant endocrinologist, Stafford Hospital and Professor John Wass, professor of endocrinology, Churchill Hospital, University of Oxford.


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus